We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dolutegravir belongs to a class of drugs called HIV-integrase inhibitors that reduce the amount of HIV in the blood while boosting immune-cell production. Read More
The advantage of using AAV as a vector is that “it can achieve sustained expression of the antibodies in the nasal mucosa, which is the site of infection, following a single administration,” said UPenn’s lead researcher James Wilson. Read More
Regeneron has partnered with the University of Pennsylvania (UPenn) to develop a gene therapy nasal delivery system for its COVID-19 antibody cocktail, casirivimab and imdevimab, which received an Emergency Use Authorization from the FDA last month for mild-to-moderately ill coronavirus patients at high risk. Read More
The global police organization Interpol issued a warning yesterday to countries to prepare for a new wave of organized criminal activity, including cyber hacking of drugmakers as governments prepare to ship their vaccines. Read More
Wren has pioneered a new approach to protein misfolding diseases that uses a predictive method in place of the traditional drug discovery and biological approaches. Read More
AstraZeneca is selling off limited rights to its former blockbuster statin drug Crestor to Grünenthal for $320 million upfront and possible future milestone payments of up to $30 million. Read More
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled. Read More
United Biomedical’s nonprofit vaccine subsidiary, Covaxx, said it has secured supply deals worth $2.8 billion for more than 140 million doses of its COVID-19 vaccine candidate, UB-612, in “multiple countries,” including Brazil, Ecuador and Peru. Read More
Merck is expanding further into the biotech sector by acquiring Rockville, Md., biopharma company OncoImmune for $425 million, netting in the process an investigational drug that has shown promise as a treatment for hospitalized COVID-19 patients. Read More